MA28579B1 - Dérivés de tétrahydronaphtyridine utiles comme ligands du récepteur d'histamine H3 - Google Patents

Dérivés de tétrahydronaphtyridine utiles comme ligands du récepteur d'histamine H3

Info

Publication number: MA28579B1
Authority: MA; Morocco
Prior art keywords: histamine; receptor ligands; derivatives useful; tetrahydronaphthyridine derivatives; tetrahydronaphthyridine
Prior art date: 2004-05-12

Application number

MA29447A

Other languages

English (en)

Inventor

Graham Lunn

John Paul Mathias

Ross Sinclair Strang

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-12

Filing date

2006-11-10

Publication date

2007-05-02

2006-11-10 Application filed by Pfizer filed Critical Pfizer

2007-05-02 Publication of MA28579B1 publication Critical patent/MA28579B1/fr

Links

ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical class C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 title 1
102000004384 Histamine H3 receptors Human genes 0.000 title 1
108090000981 Histamine H3 receptors Proteins 0.000 title 1
239000003446 ligand Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Hydrogenated Pyridines (AREA)
Pyridine Compounds (AREA)

MA29447A 2004-05-12 2006-11-10 Dérivés de tétrahydronaphtyridine utiles comme ligands du récepteur d'histamine H3 MA28579B1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04291222A EP1595881A1 (fr)	2004-05-12	2004-05-12	Dérivés de tetrahydronaphthyridine en tant que ligands de récepteur H3 d'histamine

Publications (1)

Publication Number	Publication Date
MA28579B1 true MA28579B1 (fr)	2007-05-02

Family

ID=34931096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA29447A MA28579B1 (fr)	2004-05-12	2006-11-10	Dérivés de tétrahydronaphtyridine utiles comme ligands du récepteur d'histamine H3

Country Status (32)

Country	Link
US (2)	US7557121B2 (fr)
EP (2)	EP1595881A1 (fr)
JP (1)	JP4084410B2 (fr)
KR (1)	KR100908155B1 (fr)
CN (2)	CN1950371B (fr)
AP (1)	AP2006003786A0 (fr)
AR (1)	AR049092A1 (fr)
AT (1)	ATE491707T1 (fr)
AU (1)	AU2005243403B2 (fr)
BR (1)	BRPI0510762A (fr)
CA (1)	CA2564201C (fr)
CR (1)	CR8747A (fr)
DE (1)	DE602005025345D1 (fr)
DK (1)	DK1756104T3 (fr)
EA (1)	EA010487B1 (fr)
EC (1)	ECSP066984A (fr)
ES (1)	ES2355572T3 (fr)
GE (1)	GEP20084552B (fr)
GT (1)	GT200500112A (fr)
IL (1)	IL178882A (fr)
MA (1)	MA28579B1 (fr)
MX (1)	MXPA06013113A (fr)
NL (1)	NL1029016C2 (fr)
NO (1)	NO20064577L (fr)
PA (1)	PA8632801A1 (fr)
PE (1)	PE20060312A1 (fr)
SV (1)	SV2005002112A (fr)
TN (1)	TNSN06369A1 (fr)
TW (1)	TW200607506A (fr)
UY (1)	UY28895A1 (fr)
WO (1)	WO2005111036A1 (fr)
ZA (1)	ZA200609111B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6468306B1 (en)	1998-05-29	2002-10-22	Advanced Medical Optics, Inc	IOL for inhibiting cell growth and reducing glare
BRPI0417503B1 (pt)	2003-12-09	2015-07-21	Abbott Medical Optics Inc	Lente intra-ocular dobrável
AU2006261162A1 (en) *	2005-06-17	2006-12-28	Janssen Pharmaceutica N.V.	Naphthyridine compounds
US8158673B2 (en) *	2005-10-27	2012-04-17	Pfizer Inc.	Histamine-3 receptor antagonists
JP2009514846A (ja) *	2005-11-04	2009-04-09	ファイザー・リミテッド	テトラヒドロナフチリジン誘導体
WO2007099423A1 (fr) *	2006-03-02	2007-09-07	Pfizer Products Inc.	Dérivés de 1-pyrrolidine indane en tant qu'antagonistes du récepteur d'histamine 3
WO2007106349A2 (fr)	2006-03-10	2007-09-20	Neurogen Corporation	Pipérazinyl-oxoalkyl-tétrahydroisoquinoléines et analogues apparentés
US9108948B2 (en)	2006-06-23	2015-08-18	Abbvie Inc.	Cyclopropyl amine derivatives
CA2655604C (fr)	2006-06-23	2016-08-09	Abbott Laboratories	Derives de cyclopropylamine
JP5520051B2 (ja) *	2007-11-15	2014-06-11	武田薬品工業株式会社	縮合ピリジン誘導体およびその用途
US8383657B2 (en)	2007-12-21	2013-02-26	Abbott Laboratories	Thiazolylidine urea and amide derivatives and methods of use thereof
WO2009082698A1 (fr) *	2007-12-21	2009-07-02	Abbott Laboratories	Compositions pour le traitement de troubles cognitifs
WO2009105717A1 (fr) *	2008-02-22	2009-08-27	Irm Llc	Composés et compositions comme modulateurs d'activité de gpr119
US20110046130A1 (en) *	2008-03-31	2011-02-24	Evotec Ag	Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
WO2010026113A1 (fr) *	2008-09-03	2010-03-11	Evotec Neurosciences Gmbh	Acyl- et sufonyl-tétrahydronaphtyridines et dérivés aza de celles-ci en tant qu’antagonistes de récepteur d’histamine h3
WO2010052222A1 (fr) *	2008-11-07	2010-05-14	Evotec Neurosciences Gmbh	Dérivés (dihydro)naphthyridinone comme antagonistes du récepteur h3 de l’histamine
US20120115900A1 (en) *	2009-04-21	2012-05-10	Neurosearch A/S	Substituted naphthyridine derivatives and their medical use
US9186353B2 (en)	2009-04-27	2015-11-17	Abbvie Inc.	Treatment of osteoarthritis pain
US8711772B2 (en) *	2009-05-22	2014-04-29	Qualcomm Incorporated	Paging of a user equipment (UE) within a wireless communications system
WO2011005636A1 (fr) *	2009-07-09	2011-01-13	Merck Sharp & Dohme Corp.	Antagonistes des récepteurs à l'orexine à base de tétrahydronaphtyridine
US8853390B2 (en)	2010-09-16	2014-10-07	Abbvie Inc.	Processes for preparing 1,2-substituted cyclopropyl derivatives
CN102093356B (zh) *	2011-03-16	2012-12-19	无锡美克赛医药科技有限公司	一种2-氯-5,6,7,8-四氢-1,6-萘啶盐酸盐的制备方法
WO2012131539A1 (fr)	2011-03-31	2012-10-04	Pfizer Inc.	Nouvelles pyridones bicycliques
WO2012172449A1 (fr)	2011-06-13	2012-12-20	Pfizer Inc.	Lactames convenant comme inhibiteurs des bêta-sécrétases
WO2013030713A1 (fr)	2011-08-31	2013-03-07	Pfizer Inc.	Hexahydropyrano[3,4-d][1,3]thiazine-2-amines
WO2013164730A1 (fr)	2012-05-04	2013-11-07	Pfizer Inc.	Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2
EA025186B1 (ru)	2012-06-29	2016-11-30	Пфайзер Инк.	НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
JP2015529239A (ja)	2012-09-20	2015-10-05	ファイザー・インク	アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
UA110688C2 (uk)	2012-09-21	2016-01-25	Пфайзер Інк.	Біциклічні піридинони
CA2893256A1 (fr)	2012-12-11	2014-06-19	Pfizer Inc.	Composes d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
CA2893333C (fr)	2012-12-19	2017-10-24	Pfizer Inc.	Composes hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitues carbocycliques et heterocycliques
WO2014125394A1 (fr)	2013-02-13	2014-08-21	Pfizer Inc.	Composés hexahydropyrano [3,4-d][1,3] thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en)	2013-02-15	2016-01-12	Pfizer Inc.	Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
MD20150071A2 (ro)	2013-02-19	2016-02-29	Pfizer Inc.	Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
MD20150103A2 (ro)	2013-05-02	2016-02-29	Pfizer Inc.	Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
WO2015049616A1 (fr)	2013-10-04	2015-04-09	Pfizer Inc.	Nouvelles pyridinones bicycliques utilisées comme modulateurs de gamma-sécrétase
EP3083618B1 (fr)	2013-12-17	2018-02-21	Pfizer Inc	Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituées et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituées en tant qu'inhibiteurs de la lrrk2
BR112016022519A8 (pt)	2014-04-01	2018-03-06	Pfizer	cromeno e 1,1a,2,7b-tetra-hidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gama-secretase
JP6111002B1 (ja)	2014-04-10	2017-04-05	ファイザー・インク	２−アミノ−６−メチル−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル−１，３−チアゾール−４−イルアミド
WO2016012896A1 (fr)	2014-07-24	2016-01-28	Pfizer Inc.	Composés de pyrazolopyrimidine
EA031201B1 (ru)	2014-08-06	2018-11-30	Пфайзер Инк.	Соединения имидазопиридазина
KR102000382B1 (ko)	2015-02-03	2019-07-15	화이자 인코포레이티드	신규 시클로프로파벤조푸라닐 피리도피라진디온
ES2924698T3 (es) *	2015-05-28	2022-10-10	Theravance Biopharma R&D Ip Llc	Proceso e intermedios para la preparación de compuestos de naftiridina como inhibidores de quinasa JAK
DK3310784T3 (da)	2015-06-17	2020-11-09	Pfizer	Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
RU2722149C1 (ru)	2015-09-14	2020-05-27	Пфайзер Инк.	Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
WO2017051303A1 (fr)	2015-09-24	2017-03-30	Pfizer Inc.	Dérivés de tétrahydropyrano[3,4-d] [1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace
EP3353174A1 (fr)	2015-09-24	2018-08-01	Pfizer Inc	N-[2-(3-amino-2,5-diméthyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides utiles comme inhibiteurs de bace
JP2018531923A (ja)	2015-09-24	2018-11-01	ファイザー・インク	Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
KR102148587B1 (ko)	2016-02-23	2020-08-26	화이자 인코포레이티드	6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물
PL3478679T3 (pl)	2016-07-01	2021-10-25	Pfizer Inc.	Pochodne 5,7-dihydro-pirolopirydyny do leczenia chorób neurologicznych i neurodegeneracyjnych
SG10202110112TA (en)	2017-03-10	2021-10-28	Pfizer	Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
ES2910083T3 (es)	2017-03-10	2022-05-11	Pfizer	Derivados de imidazo[4,5-c]quinolina cíclicos sustituidos
WO2018226992A1 (fr)	2017-06-07	2018-12-13	Adrx, Inc.	Inhibiteur d'agrégation de tau
FI3642202T3 (fi)	2017-06-22	2023-03-01		Dihydro-pyrrolo-pyridiinijohdannaisia
CA3073062A1 (fr)	2017-08-18	2019-02-21	Adrx, Inc.	Inhibiteurs peptidiques d'agregation de tau
EP3768669B1 (fr)	2018-03-23	2023-01-25	Pfizer Inc.	Dérivés azaspiro de pipérazine
EP4297868A4 (fr)	2021-02-23	2025-01-08	Hoth Therapeutics, Inc.	Utilisation d'aprépitant pour le traitement de la maladie d'alzheimer
CN117279917A (zh) *	2021-05-21	2023-12-22	成都百裕制药股份有限公司	哌嗪衍生物及其在医药上的应用
AU2024413926A1 (en)	2023-12-29	2026-07-09	Pfizer Inc.	Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0882023B1 (fr)	1996-02-09	2003-06-04	James Black Foundation Limited	Ligands du recepteur de l'histamine h 3
WO2000035298A1 (fr)	1996-11-27	2000-06-22	Wm. Wrigley Jr. Company	Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
GB9803536D0 (en)	1998-02-19	1998-04-15	Black James Foundation	Histamine H,receptor ligands
EP0982300A3 (fr)	1998-07-29	2000-03-08	Societe Civile Bioprojet	Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique
TWI298068B (en) *	2000-06-21	2008-06-21	Dainippon Sumitomo Pharma Co	Pharmaceutical composition for schizophrenia
JP4516717B2 (ja)	2000-07-13	2010-08-04	アボット・ラボラトリーズ	ヒスタミン−３受容体リガンドとしての１，３−二置換ピロリジン及び１，３，３−三置換ピロリジン並びにそれらの治療的応用
CZ2003686A3 (cs)	2000-08-08	2003-08-13	Ortho Mcneil Pharmaceutical, Inc.	Neimidazolové aryloxypiperidiny
CA2418369A1 (fr) *	2000-08-08	2002-02-14	Richard Apodaca	Aryloxyalkylamines exemptes de fraction imidazole
JP2004532834A (ja)	2001-03-23	2004-10-28	イーライ・リリー・アンド・カンパニー	ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
GB0206033D0 (en) *	2002-03-14	2002-04-24	Pfizer Ltd	Compounds useful in therapy
MXPA06001053A (es)	2003-07-29	2006-04-11	Novo Nordisk As	Piridazinil-piperazinas y su uso como ligandos del receptor de histamina h3.
JP2009514846A (ja) *	2005-11-04	2009-04-09	ファイザー・リミテッド	テトラヒドロナフチリジン誘導体

2004
- 2004-05-12 EP EP04291222A patent/EP1595881A1/fr not_active Withdrawn
2005
- 2005-05-06 JP JP2007512575A patent/JP4084410B2/ja not_active Expired - Fee Related
- 2005-05-06 CA CA2564201A patent/CA2564201C/fr not_active Expired - Fee Related
- 2005-05-06 AU AU2005243403A patent/AU2005243403B2/en not_active Ceased
- 2005-05-06 GE GEAP20059701A patent/GEP20084552B/en unknown
- 2005-05-06 CN CN2005800150008A patent/CN1950371B/zh not_active Expired - Fee Related
- 2005-05-06 DE DE602005025345T patent/DE602005025345D1/de not_active Expired - Lifetime
- 2005-05-06 EP EP05736116A patent/EP1756104B1/fr not_active Expired - Lifetime
- 2005-05-06 MX MXPA06013113A patent/MXPA06013113A/es active IP Right Grant
- 2005-05-06 CN CN201010150783A patent/CN101798305A/zh active Pending
- 2005-05-06 KR KR1020067023573A patent/KR100908155B1/ko not_active Expired - Fee Related
- 2005-05-06 DK DK05736116.4T patent/DK1756104T3/da active
- 2005-05-06 WO PCT/IB2005/001267 patent/WO2005111036A1/fr not_active Ceased
- 2005-05-06 BR BRPI0510762-8A patent/BRPI0510762A/pt not_active IP Right Cessation
- 2005-05-06 AT AT05736116T patent/ATE491707T1/de not_active IP Right Cessation
- 2005-05-06 ES ES05736116T patent/ES2355572T3/es not_active Expired - Lifetime
- 2005-05-06 EA EA200601897A patent/EA010487B1/ru not_active IP Right Cessation
- 2005-05-06 AP AP2006003786A patent/AP2006003786A0/xx unknown
- 2005-05-11 TW TW094115276A patent/TW200607506A/zh unknown
- 2005-05-11 NL NL1029016A patent/NL1029016C2/nl not_active IP Right Cessation
- 2005-05-11 AR ARP050101916A patent/AR049092A1/es unknown
- 2005-05-12 GT GT200500112A patent/GT200500112A/es unknown
- 2005-05-12 PE PE2005000533A patent/PE20060312A1/es not_active Application Discontinuation
- 2005-05-12 SV SV2005002112A patent/SV2005002112A/es not_active Application Discontinuation
- 2005-05-12 UY UY28895A patent/UY28895A1/es not_active Application Discontinuation
- 2005-05-12 PA PA20058632801A patent/PA8632801A1/es unknown
- 2005-05-12 US US11/128,804 patent/US7557121B2/en not_active Expired - Fee Related
2006
- 2006-10-09 NO NO20064577A patent/NO20064577L/no not_active Application Discontinuation
- 2006-10-26 IL IL178882A patent/IL178882A/en not_active IP Right Cessation
- 2006-11-01 ZA ZA200609111A patent/ZA200609111B/xx unknown
- 2006-11-09 EC EC2006006984A patent/ECSP066984A/es unknown
- 2006-11-10 CR CR8747A patent/CR8747A/es unknown
- 2006-11-10 TN TNP2006000369A patent/TNSN06369A1/fr unknown
- 2006-11-10 MA MA29447A patent/MA28579B1/fr unknown
2009
- 2009-06-25 US US12/491,370 patent/US20090258861A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2564201A1 (fr)	2005-11-24
EP1756104B1 (fr)	2010-12-15
AR049092A1 (es)	2006-06-28
WO2005111036A1 (fr)	2005-11-24
KR20070014174A (ko)	2007-01-31
NO20064577L (no)	2006-11-06
MXPA06013113A (es)	2007-02-28
TW200607506A (en)	2006-03-01
IL178882A0 (en)	2007-03-08
ES2355572T3 (es)	2011-03-29
US20050256135A1 (en)	2005-11-17
TNSN06369A1 (fr)	2008-02-22
CA2564201C (fr)	2011-01-18
GT200500112A (es)	2005-12-12
DE602005025345D1 (de)	2011-01-27
EA200601897A1 (ru)	2007-02-27
US20090258861A1 (en)	2009-10-15
AP2006003786A0 (en)	2006-10-31
NL1029016A1 (nl)	2005-11-15
EP1595881A1 (fr)	2005-11-16
EA010487B1 (ru)	2008-10-30
ZA200609111B (en)	2008-08-27
ATE491707T1 (de)	2011-01-15
KR100908155B1 (ko)	2009-07-16
SV2005002112A (es)	2005-12-13
AU2005243403B2 (en)	2010-10-07
AU2005243403A1 (en)	2005-11-24
EP1756104A1 (fr)	2007-02-28
UY28895A1 (es)	2005-12-30
CN1950371B (zh)	2011-01-12
IL178882A (en)	2011-03-31
NL1029016C2 (nl)	2006-05-30
CN101798305A (zh)	2010-08-11
CR8747A (es)	2006-12-05
DK1756104T3 (da)	2011-02-21
BRPI0510762A (pt)	2007-11-20
GEP20084552B (en)	2008-11-25
ECSP066984A (es)	2006-12-29
PA8632801A1 (es)	2006-06-02
PE20060312A1 (es)	2006-05-03
JP4084410B2 (ja)	2008-04-30
JP2007536374A (ja)	2007-12-13
CN1950371A (zh)	2007-04-18
US7557121B2 (en)	2009-07-07

Publication	Publication Date	Title
AP2006003786A0 (en)	2006-10-31	Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands
MA28391B1 (fr)	2007-01-02	Dérivés de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de récepteurs de chimiokines
DK1797099T3 (da)	2010-11-29	Piperidinylamino-thieno[2,3-D]pyrimidinforbindelser
EP1613961A4 (fr)	2007-03-07	Complexes de recepteurs de surface utilises comme biomarqueurs
EP1937825A4 (fr)	2010-06-23	4'-nucleosides modifies utiles comme agents antiviraux
EP2103619A4 (fr)	2011-11-23	Dérivés d'imidazothiazole
MA28798B1 (fr)	2007-08-01	Dérivés de triazolopyridinylsufanyle servant d'inhibiteurs de kinase MAP P38
EP2032566A4 (fr)	2009-07-08	Dérivés d'azétidine comme inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
IL174400A0 (en)	2006-08-01	Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acety lcholine receptors
ZA200806071B (en)	2009-04-29	Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
ZA200700683B (en)	2008-08-27	Piperidine derivatives as histamine H3 receptor ligands
SI1710241T1 (sl)	2010-02-26	Intermediatne spojine za pripravo trans-5-kloro-2-metil-2,3,3a, 12b-tetrahidro-1H-dibenz(2,3:6,7)oksepino(4,5-C)pirola
EP2138484A4 (fr)	2012-01-11	Dérivés d'hétéro-aryle bicyclique fusionnés
EP1951061A4 (fr)	2011-04-27	Méthode de modification de la texture d'une préparation
DK1802307T3 (da)	2008-06-30	Pyrrolidinderivater som histamin-receptor-ligander
EP1810969A4 (fr)	2011-05-25	Dérivés de benzimidazole aryloxy-substitués
EP1951231A4 (fr)	2010-09-22	Derives de camptothecine utiles comme agents chimioradiosensibles
ATE306265T1 (de)	2005-10-15	Benzothiazolderivate als adenosin-rezeptor- liganden
FR2875971B1 (fr)	2006-11-10	Convertisseur alternatif-continu pour l'aeronautique
DE60305058D1 (de)	2006-06-08	Imidazoquinoline derivate als adenosine a3 rezeptor liganden
EP1750351A4 (fr)	2015-04-01	Alternateur pour véhicule
DK1838683T3 (da)	2009-08-10	Fremgangsmåde til fremstilling af [1,4,5]-oxadiazepinderivater
EP1714656A4 (fr)	2012-10-31	Preparation de l'ed-71
SI1636223T1 (sl)	2008-06-30	Derivati benzotiazola kot ligandi receptorja adenozina
EP1786433A4 (fr)	2008-02-27	Derives de betulinol utilises en tant qu'agents anti-vih